IRONWOOD PHARMACEUTICALS, INC. Accounts Receivable, Allowance for Credit Loss
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Accounts Receivable, Allowance for Credit Loss of $0 as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-02-26
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2024-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2023-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2022-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-16 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |